首页/数据集/Median progression-free survival by lines of treatment.

Median progression-free survival by lines of treatment.

NIAID Data Ecosystem2026-05-02 收录

抗肿瘤药物疗效评估

临床医学研究

数据链接：

https://figshare.com/articles/dataset/Median_progression-free_survival_by_lines_of_treatment_/25841101 数据链接链接失效反馈

官方服务：

资源简介：

Median progression-free survival by lines of treatment.

应用场景：

创建时间：

2024-05-16

临床医学研究

系统评价元数据

Abbreviations: US, United States;UK, United Kingdom; BMT, Bone Marrow Transplant; ESRD, End Stage Renal Disease; GPRD – general practice research database; IBD, Inflammatory Bowel Disease; CD, Clostri

NIAID Data Ecosystem80

Clinical manifestations related to TSM-associated IRIS in IRIS group.

免疫重建炎症综合症

临床医学研究

Clinical manifestations related to TSM-associated IRIS in IRIS group.

Figshare2024-10-18 更新30

Characteristics of the propensity score-matched patients according to the presence of diabetes mellitus.

临床医学研究

糖尿病队列分析

Characteristics of the propensity score-matched patients according to the presence of diabetes mellitus.

Figshare2018-12-10 更新30

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

转移性结直肠癌维持与支持治疗

抗肿瘤药物疗效评估

PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main

NIAID Data Ecosystem40

The comparison of pepsinogen levels between patients with and without GERD.

胃食管反流病生物标志物

临床医学研究

The comparison of pepsinogen levels between patients with and without GERD.

NIAID Data Ecosystem30